Both in Pharmaceuticals
Lipocine vs Marker Therapeutics
Over the past year LPCN returned −23.1% and MRKR returned +18.8%; their daily moves had a correlation of -0.02.
LPCN −23.1% MRKR +18.8%Growth of $1, one year, split-adjusted
| Metric | LPCN | MRKR |
|---|---|---|
| Price | $2.16 | $1.10 |
| Market cap | $17.8M | $18.3M |
| Today | +3.35% | −2.22% |
| 1 month | −0.5% | −19.7% |
| 6 months | −71.5% | −11.3% |
| Year to date | −73.1% | −26.2% |
| 1 year | −20.9% | +15.8% |
| Revenue growth (YoY) | −100.0% | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 14.1× | 7.8× |
| Net cash | $23.3M | $11.3M |
| Dividend yield | — | — |
| Volatility (60d) | 35.4% | 70.8% |
| Short % of float | 1.3% | 1.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).